Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction

Demir E. , Balal M. , Paydas S. , Sertdemir Y. , ERKEN U.

TRANSPLANTATION PROCEEDINGS, cilt.38, ss.1379-1381, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Erectile dysfunction (ED) profoundly affects the quality of life. The prevalence of ED in renal transplant recipients is reported by high as 50% to 60%. We evaluated the efficacy and safety of vardenafil in these patients with ED as well as its effects on graft function and on cylosporine or tacrolimus concentrations. Thirty-nine recipients with ED and serum creatinine values < 2 mg/dL were treated with vardenafil. ED was assessed using the self-administered International Index of Erectile Function (IIEF). ED was diagnosed by using penile color-Doppler ultrasonography and intracavernosal injection. Vardenafil efficacy was assessed by readministering the IIEF questionnaire after 4 weeks of therapy. Serum creatinine levels, creatinine clearances, and cyclosporine/tacrolimus concentrations were measured before and after vardenafil therapy. Twenty-one recipients with ED served as placebo controls and 15 without ED as another control group. The IIEF scores improved from 12.80 +/- 3.5 to 26.46 +/- 2.4 in vardenafil-treated patients with ED (P < .001). Renal function and cyclosporine/tacrolimus concentrations did not change with vardenafil therapy. Side effects were, observed in 7 (18%) patients: headache in three, palpitations in one, flushing in two, and dyspepsia in one. This study demonstrated that ED improved with vardenafil in renal transplant recipients with ED. For 4 weeks vardenafil therapy was free of side effects. Renal function tests did not change. Also, no dose change in immunosuppressive drugs was required during 4 weeks of verdanafil therapy.